Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

dy will be included in the approved prescribing information in the U.S. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and Pharmion undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

The scientific information discussed in this press release is preliminary and investigative. Vidaza has not yet been approved by the EMEA in the EU and the results described in this press release have not been approved for inclusion in the prescribing information for Vidaza by the FDA in the U.S. or any other regulatory authority.


'/>"/>
SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   ... II study investigating the efficacy and safety of MSB0010718C in ... is a rare and aggressive skin cancer lacking effective treatments   ... seven cohort Phase I clinical trial for the treatment of ... EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ...
(Date:7/28/2014)... -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) ... audio webcast to discuss financial results for the second quarter ... 31, 2014 at 4:30 p.m. ET. Conference ... 31, 2014 Time: 4:30 PM ET Listen via Internet: ... A webcast replay will be available on the Pharmacyclics ...
(Date:7/28/2014)... FRANCISCO , July 28, 2014  Dignity ... it has received the Get With The Guidelines®-Stroke ... improvement measures outlined by the American Heart Association/American ... Stroke is the number four cause of death ... the United States , according ...
Breaking Medicine Technology:EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... 17 Mach 7 Technologies, a global provider of ... product distribution agreement with Data Distributing, an international leader ... the medical industry. Under the terms of the agreement, ... an Enterprise Image Management Platform, in the United States. ...
... , , ALISO VIEJO, Calif., Nov. ... executives from over 425 companies to discuss promising technology and ... the 4th Annual CA Medical Device & Investor Forum. ... from the biggest M&A transactions in Orange County history discussed ...
Cached Medicine Technology:Mach 7 Technologies and Data Distributing Sign Agreement for U.S. Distribution of Enterprise Image Management Solutions 2OCTANe's Medical Device & Investor Forum Highlights Key Trends, Investment Opportunities 2
(Date:7/28/2014)... 2014 A leading proposal to temporarily ... trust fund by reallocating payroll taxes has virtually no ... The Senior Citizens League (TSCL) . Less ... from the Social Security retirement trust fund to pay ... disability program’s financing. “TSCL believes this ‘band aid’ approach ...
(Date:7/28/2014)... The “Tissue Diagnostics Market by ... & Workflow, Special Staining), Disease (Breast Cancer, ... Cell Lung Cancer and Others), Product (Instruments ... Laboratories, Contract Research Organizations and Others) & ... & RoW) - Trends & Forecast to ...
(Date:7/28/2014)... A January 2013 study published ... in those who were self-diagnosed gluten-intolerant yielded little verifiable ... for San Diego health and wellness retreat VeraVia ... those who are unclear about the role gluten plays ... a protein, found in wheat, barley, rye, and triticale. ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... milliseconds to look at someone,s face and judge them good-looking ... certain facial features seem to trigger specific first impressions about ... the mouth, for example, appear directly linked to whether someone ... The study findings suggest that first impressions are fairly ...
(Date:7/28/2014)... Shofner Vision Center recently wrapped ... Renowned LASIK and Cataract Surgeon, Dr. Stewart Shofner ... and public awareness for local not-for-profit organizations that ... their families. “This was our 2nd annual summer ... to a variety of local not-for-profit organizations who ...
Breaking Medicine News(10 mins):Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 2Health News:The Senior Citizens League Finds No Support Among Seniors for Likely Disability Trust Fund Fix 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3
... CHICAGO Jorge Sobenes is a husband and father who loves ... he went from enjoying his favorite foods to not being able ... and difficulty swallowing. He lost 40 pounds and was desperate ... the esophagus is unable to move food into the stomach, and ...
... with hepatocellular carcinoma (HCC) is achievable using 90Y-resin ... across Europe showed that the procedure is likely ... including patients with advanced liver cancer and with ... to dateare published in the September issue of ...
... -- An experimental drug that,s shown promise against ovarian cancer ... also be effective against ovarian cancer not caused by those ... the activity of a protein called poly ADP ribose polymerase ... repair. Clinical trials of olaparib in patients with BRCA 1 ...
... HealthDay Reporter , MONDAY, Aug. 22 (HealthDay News) -- ... also appears linked to a decline in mammograms, new research ... 50 to 64 reduced their hormone therapy use from 41 ... study lead author Nancy Breen, an economist with the U.S. ...
... can act as "weight shocks," leading people to add a few ... to a new study. But when it comes to large ... men than they are for women. For men, the risk ... But for women, the risk of a large weight gain was ...
... HealthDay Reporter , SATURDAY, Aug. 20 (HealthDay News) -- Working ... stay-at-home moms, a new study finds. However, working moms ... about how easy it will be to balance work and ... counterparts. , , Researchers analyzed survey results from 1,600 married ...
Cached Medicine News:Health News:Incisionless surgery now available as an investigational treatment for esophageal disorder 2Health News:Radioembolization improves chance of survival for liver cancer patients 2Health News:Trial Drug Shows Preliminary Promise Against Ovarian Cancer 2Health News:Decline in Hormone Therapy Linked to Fewer Mammograms 2Health News:Large weight gains most likely for men after divorce, women after marriage 2Health News:Large weight gains most likely for men after divorce, women after marriage 3Health News:Trying to Be 'Supermom' Can Raise Risk for Depression 2Health News:Trying to Be 'Supermom' Can Raise Risk for Depression 3
This is adapted to microplate or card....
Bio-Rad's ScanGel® cards for blood typing provide standardized protocols for all the cards: same incubation time (if required), same centrifugation time and speed....
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
... cell accommodates up to 12 large slab ... in the PROTEAN IEF system, for high-throughput ... PROTEAN Plus Dodeca cell's cooling and recirculating ... consistent, high-resolution results. The handcasting system includes ...
Medicine Products: